Selinexor in Myelofibrosis Refractory or Intolerant to JAK1/2 Inhibitors
Status:
Recruiting
Trial end date:
2025-03-14
Target enrollment:
Participant gender:
Summary
This is a phase II, open label, prospective, single-arm study evaluating the efficacy and
safety of selinexor in patients with PMF or secondary MF (PPV-MF or PET-MF) who are
refractory or intolerant to ruxolitinib and/or any other experimental JAK1/2 inhibitors.